Skip to main content

Table 1 Baseline demographics

From: Cardiovascular Risk and Disease Among Masters Endurance Athletes: Insights from the Boston MASTER (Masters Athletes Survey To Evaluate Risk) Initiative

 

Total

Men (n = 391)

Women (n = 200)

p value

Age, years

50 ± 9

51 ± 9

48 ± 9

0.001

Height, cm

174.8 ± 13.7

179.3 ± 11.2

165.9 ± 13.7

<0.001

Weight, kg

72.9 ± 13.0

78.6 ± 10.7

61.9 ± 9.8

<0.001

Body mass index, kg/m2

23.4 ± 3.6

22.4 ± 2.8

24.0 ± 3.8

<0.001

Marital status

    

 Married/committed relationship

490/591 (82.9)

349/391 (89.3)

141/200 (70.5)

<0.001

 Single

52/591 (8.8)

24/391 (6.1)

28/200 (14.0)

0.001

 Divorced

47/591 (8.0)

18/391 (4.6)

29/200 (14.5)

<0.001

Children

426/591 (72.1)

314/391 (80.3)

112/200 (56.0)

<0.001

Religious

200/591 (33.8)

136/391 (34.8)

64/200 (32.0)

0.498

Medication use

    

 Lipid lowering

40/591 (6.8)

35/391 (8.9)

5/200 (2.5)

0.003

 Antidepressants

39/591 (6.6)

14/391 (3.6)

25/200 (12.5)

<0.001

 Blood pressure medications

36/591 (6.1)

26/391 (6.6)

10/200 (5.0)

0.427

 Thyroid replacement therapy

34/591 (5.8)

12/391 (3.1)

22/200 (11.0)

<0.001

 Aspirin/anticoagulants

30/391 (5.1)

26/391 (6.6)

4/200 (2.0)

0.003

 Pain medications

19/591 (3.2)

11/391 (2.8)

8/200 (4.0)

0.465

 Asthma/allergy

19/591 (3.2)

10/391 (2.6)

9/200 (4.5)

0.223

 Othera

18/591 (3.0)

11/391 (2.8)

7/200 (3.5)

0.622

 OC/hormone replacement therapy

10/591 (1.7)

0/391 (0.0)

10/200 (5.0)

N/A

 BPH medications/sildenafil

5/591 (0.8)

5/391 (1.3)

0/200 (0.0)

N/A

 Arrhythmia drugs

3/591 (0.5)

2/391 (0.5)

1/200 (0.5)

1.000

  1. Values are mean ± SD or n (%); p values reflect significance of difference between men and women
  2. BPH benign prostatic hyperplasia, OC oral contraceptive, N/A not applicable
  3. aIncludes allopurinol, antiseizure, biologics, and immunosuppressants